Diagnosing Sepsis in Minutes

Sepsis is a healthcare condition with “incredible unmet need,” Ajay Shah, cofounder and CEO of Cytovale, tells MD+DI. “More people die from sepsis than from breast cancer, prostate cancer, and AIDS combined each year, and it costs more than $20 billion a year to treat sepsis in the United States.” Complicating matters is that sepsis “is challenging to diagnose early in the emergency department,” he added. Cytovale is hoping to tackle sepsis through early diagnosis. The company is developing a diagnostic test that could be used “close to care” to “rapidly diagnose sepsis in minutes,” said Shah. The technology is based on microfluidics research by Cytovale cofounder and scientific advisor Dino Di Carlo performed in UCLA’s bioengineering department (where he serves as professor and runs the Di Carlo Lab) and by fellow cofounder and CTO Henry Tse. Cytovale’s core platform uses microfluidics, ultrahigh-speed imaging, computer-based vision, and machine learning to measure the biomechanical properties of thousands of individual cells. To help Cytovale further develop the platform, the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Respons...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news